Abstract 462P
Background
The aim of this study was to identify correlates of cognitive function among cancer survivors attending rehabilitation in a community setting.
Methods
Participants were 35 cancer patients who had reported memory issues and were screened by an occupational therapist for cognitive dysfunction. Using baseline data, descriptive and bivariate analyses were performed to detail the cognitive function of study sample and to identify its correlates.
Results
Study sample was predominantly female (94.7%) with breast cancer (65.8%) who had received chemotherapy (77.1%) and hormonal therapy (51.5%). Mean age was 53.8 ± 10.3 years and mean years since diagnosis was 4.9 ± 3.3 years. Mean scores of cognitive performances were within the norms for attention (digit span forward test; 7.5 ± 1.4), working memory (digit span backward test; 5.4 ± 1.3), processing speed (trail making test A; 25.1 ± 5.5), and executive function (trail making test B; 68.3 ± 33.6). Mean scores of perceived cognitive ability (15.5 ± 4.1) and cognitive-related quality of life (9.8 ± 3.7), measured by the FACT-Cog, were below the norms. Cancer survivors with more years since diagnosis performed better in executive function (r = .45). Poorer working memory (r = -.38) and lower cognitive-related quality of life (r = -.41) were also found to associate with increased fatigue intensity. Although sleep duration and distress rating were not related to cognitive function, shorter sleep duration (r = -.35) and higher distress rating (r = .37) correlated with higher fatigue intensity. All results were statistically significant at p < 0.05.
Conclusions
Cancer survivors may report reduced perceived cognitive ability and cognitive-related quality of life despite adequate performance on objective tests. This discrepancy could be due to the relationship of fatigue to working memory. Global evaluation of cognitive function considers cognitive performance during periods of more intense fatigue while objective tests provide information on cognitive performance when tested at a particular time and fatigue level. Managing fatigue including addressing distress and sleep issues may be potential strategies that can be employed to support cognitive function.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract